Monitoring oxidative stress in acute-on-chronic liver failure by advanced oxidation protein products

Hepatology Research

Volumn 42, Issue 2, 2012, Pages 171-180

  Liu, Hua ^a   Han, Tao ^a   Tian, Jie ^a   Zhu, Zheng Yan ^a   Liu, Ying ^a   Li, Yan ^a   Xiao, Shi Xiang ^a   Li, Ying ^a   Feng, Yu Ying ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Acute on chronic liver failure; Advanced oxidation protein products; Oxidative stress; Plasma exchange

Indexed keywords

ADVANCED OXIDATION PROTEIN PRODUCT; BILIRUBIN; BIOLOGICAL MARKER; CYTOKERATIN 18;

ACUTE LIVER FAILURE; ADULT; APOPTOSIS; ARTICLE; CHRONIC LIVER FAILURE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEPATITIS B; HUMAN; LIVER CIRRHOSIS; MALE; MONITORING; OXIDATIVE STRESS; PATHOGENESIS; PLASMAPHERESIS; PRIORITY JOURNAL; PROGNOSIS; SPECTROPHOTOMETRY; TREATMENT OUTCOME;

EID: 84862972904     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2011.00911.x     Document Type: Article

References (38)

1. Custer B, Sullivan SD, Hazlet TK, Iloeje U, Veenstra DL, Kowdley KV. Global epidemiology of hepatitis B virus. J Clin Gastroenterol 2004; 38: 158-68.
2. Escorsell Mañosa A, Mas Ordeig A. Acute on chronic liver failure. Gastroenterol Hepatol 2010; 33: 126-34.
3. Sarin SK, Kumar A, Almeida JA etal. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). Hepatol Int 2009; 3: 269-82.
4. Li LJ, Zhang YM, Liu XL etal. Artificial liver support system in China: a review over the last 30years. Ther Apher Dial 2006; 10: 160-7.
5. Oettl K, Stadlbauer V, Krisper P, Stauber RE. Effect of extracorporeal liver support by molecular adsorbents recirculating system and Prometheus on redox state of albumin in acute-on-chronic liver failure. Ther Apher Dial 2009; 13: 431-6.
6. Jalan R, Williams R. Acute-on-chronic liver failure: pathophysiological basis of therapeutic options. Blood Purif 2002; 20: 252-61.
7. Witko-Sarsat V, Friedlander M, Capeillère-Blandin C etal. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 1996; 49: 1304-13.
8. Kalousová M, Fialová L, Skrha J etal. Oxidative stress, inflammation and autoimmune reaction in type 1 and type 2 diabetes mellitus. Prague Med Rep 2004; 105: 21-8.
9. Collado S, Coll E, Deulofeu R etal. Prevalence of cardiovascular disease in uraemia and relevance of cardiovascular risk factors. Nefrologia 2010; 30: 342-8.
10. Selmeci L, Seres L, Antal M, Lukács J, Regöly-Mérei A, Acsády G. Advanced oxidation protein products (AOPP) for monitoring oxidative stress in critically ill patients: a simple, fast and inexpensive automated technique. Clin Chem Lab Med 2005; 43: 294-7.
11. Iwao Y, Anraku M, Hiraike M etal. The structural and pharmacokinetic properties of oxidized human serum albumin, advanced oxidation protein products (AOPP). Drug Metab Pharmacokinet 2006; 21: 140-6.
12. Piwowar A. Advanced oxidation protein products. Part I. Mechanism of the formation, characteristics and property. Pol Merkur Lekarski 2010; 28: 166-9.
13. Oettl K, Stadlbauer V, Petter F etal. Oxidative damage of albumin in advanced liver disease. Biochim Biophys Acta 2008; 1782: 469-73.
14. Witko-Sarsat V, Friedlander M, Nguyen Khoa T etal. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 1998; 161: 2524-32.
15. Guicciardi ME, Gores GJ. Apoptosis: a mechanism of acute and chronic liver injury. Gut 2005; 54: 1024-33.
16. Feldstein AE, Wieckowska A, Lopez AR, Liu YC, Zein NN, McCullough AJ. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 2009; 50: 1072-8.
17. Bantel H, Lügering A, Heidemann J etal. Detection of apoptotic caspase activation in sera from patients with chronic HCV infection is associated with fibrotic liver injury. Hepatology 2004; 40: 1078-87.
18. Kamath PS, Wiesner RH, Malinchoc M etal. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33: 464-70.
19. Radosavljević T, Mladenović D, Vucević D. The role of oxidative stress in alcoholic liver injury. Med Pregl 2009; 62: 547-53.
20. Moreno-Otero R, Trapero-Marugán M. Hepatoprotective effects of antioxidants in chronic hepatitis C. World J Gastroenterol 2010; 16: 1937-8.
21. Kathirvel E, Chen P, Morgan K, French SW, Morgan TR. Oxidative stress and regulation of anti-oxidant enzymes in cytochrome P4502E1 transgenic mouse model of non-alcoholic fatty liver. J Gastroenterol Hepatol 2010; 25: 1136-43.
22. Bhatia V, Bhardwaj P, Elikkottil J, Batra J, Saraya A. A 7-day profile of oxidative stress and antioxidant status in patients with acute liver failure. Hepatol Int 2008; 2: 465-70.
23. Das J, Ghosh J, Manna P, Sil PC. Acetaminophen induced acute liver failure via oxidative stress and JNK activation: protective role of taurine by the suppression of cytochrome P450 2E1. Free Radic Res 2010; 44: 340-55.
24. Sen S, Williams R, Jalan R. The pathophysiological basis of acute-on-chronic liver failure. Liver 2002; 22 (Suppl 2): 5-13.
25. Volkmann X, Anstaett M, Hadem J etal. Caspase activation is associated with spontaneous recovery from acute liver failure. Hepatology 2008; 47: 1624-33.
26. Zuwała-Jagiełło J, Pazgan-Simon M, Simon K, Warwas M. Elevated advanced oxidation protein products levels in patients with liver cirrhosis. Acta Biochim Pol 2009; 56: 679-85.
27. Dohi K, Mochizuki Y, Satoh K etal. Transient elevation of serum bilirubin (a heme oxygenase-1 metabolite) level in hemorrhagic stroke: Bilirubin is a marker of oxidant stress. Acta Neurochir Suppl 2003; 86: 247-9.
28. Kalousová M, Zima T, Tesar V, Lachmanová J. Advanced glycation protein products and advanced oxidation protein products in hemodialyzed patients. Blood Purif 2002; 20: 531-6.
29. Rikker C. Liver support systems today. Orv Hetil 2009; 150: 2299-307.
30. Li LJ, Yang Q, Huang JR, Xu XW, Chen YM, Fu SZ. Effect of artificial liver support system on patients with severe viral hepatitis: a study of four hundred cases. World J Gastroenterol 2004; 10: 2984-8.
31. Yu JW, Sun LJ, Zhao YH, Li SC. Prediction value of model for end-stage liver disease scoring system on prognosis in patients with acute-on-chronic hepatitis B liver failure after plasma exchange and lamivudine treatment. J Gastroenterol Hepatol 2008; 23: 1242-9.
32. George JN. Thrombotic thrombocytopenic purpura. N Engl J Med 2006; 354: 1927-35.
33. Tesar V, Jelínková E, Jirsa M Jr, Bakosová M, Pitha P, Chábová V. Soluble adhesion molecules and cytokines in patients with myasthenia gravis treated by plasma exchange. Blood Purif 2000; 18: 115-20.
34. Zhang ZH, Liu SX, Hou FF etal. Advanced oxidation protein products-induced tumor necrosis factor alpha secretion in monocytes via reactive oxygen species generation. Di Yi Jun Yi Da Xue Xue Bao 2005; 25: 493-7.
35. Zou Z, Li B, Xu D etal. Imbalanced intrahepatic cytokine expression of interferon-gamma, tumor necrosis factor-alpha, and interleukin-10 in patients with acute-on-chronic liver failure associated with hepatitis B virus infection. J Clin Gastroenterol 2009; 43: 182-90.
36. Xing T, Li L, Cao H, Huang J. Altered immune function of monocytes in different stages of patients with acute on chronic liver failure. Clin Exp Immunol 2007; 147: 184-8.
37. Lian ZX, Okada T, He XS etal. Heterogeneity of dendritic cells in the mouse liver: identification and characterization of four distinct populations. J Immunol 2003; 170: 2323-30.
38. Alderman CJ, Shah S, Foreman JC, Chain BM, Katz DR. The role of advanced oxidation protein products in regulation of dendritic cell function. Free Radic Biol Med 2002; 32: 377-85.